KYNTRA BIO, INC. - 8-K Filing
Kyntra Bio reported Q1 2026 revenue of $3.7 million and a net loss of $15.1 million ($3.74 per share), compared to $2.7 million revenue and a $16.8 million ($4.15/share) loss in the same period last year. The company holds $100.3 million in cash, investments, and accounts receivable as of March 31, 2026, providing funding through 2028. Key updates include progress on its FG-3246 Phase 2 trial for mCRPC with an interim analysis expected by Q4 2026 and finalizing the pivotal Phase 3 protocol for roxadustat in LR-MDS following FDA feedback. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $FGEN